<DOC>
	<DOCNO>NCT00132652</DOCNO>
	<brief_summary>This study conduct compare safety effectiveness switch treatment lamivudine telbivudine ( LdT ) continue lamivudine treatment . Results patient take lamivudine switch telbivudine compare result patient continued lamivudine alone .</brief_summary>
	<brief_title>Switching Therapy From Lamivudine Telbivudine Versus Continued Lamivudine Adults With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented clinical history compatible chronic hepatitis B Patient compensate liver disease Patient receive previous treatment lamivudine duration least 3 month 12 month Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding Patient coinfected hepatitis C , hepatitis D HIV Patient previously receive antiviral treatment hepatitis B lamivudine precede 12 month Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>